ACS Medicinal Chemistry Letters
Letter
(6) Casaluce, F.; Sgambato, A.; Maione, P.; Rossi, A.; Ferrara, C.;
Napolitano, A.; Palazzolo, G.; Ciardiello, F.; Gridelli, C. ALK
inhibitors: a new targeted therapy in the treatment of advanced
NSCLC. Targeted Oncol. 2013, 8, 55−67.
(7) Lovly, C. M.; Heuckmann, J. M.; de Stanchina, E.; Chen, H.;
Thomas, R. K.; Liang, C.; Pao, W. Insights into ALK-driven cancers
revealed through development of novel ALK tyrosine kinase inhibitors.
Cancer Res. 2011, 71, 4920−4931.
(8) Mologni, L. Inhibitors of the anaplastic lymphoma kinase. Expert
Opin. Invest. Drugs 2012, 21, 985−994.
(9) Galetta, D.; Rossi, A.; Pisconti, S.; Colucci, G. The emerging role
of ALK inhibitors in the treatment of advanced non-small cell lung
cancer. Expert Opin. Ther. Targets 2012, 16, S45−S54.
(10) Christensen, J. G.; Zou, H. Y.; Arango, M. E.; Li, Q.; Lee, J. H.;
McDonnell, S. R.; Yamazaki, S.; Alton, G. R.; Mroczkowski, B.; Los, G.
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of
anaplastic lymphoma kinase and c-Met, in experimental models of
anaplastic large-cell lymphoma. Mol. Cancer Ther. 2007, 6, 3314−3322.
(11) Zou, H. Y.; Li, Q.; Lee, J. H.; Arango, M. E.; McDonnell, S. R.;
Yamazaki, S.; Koudriakova, T. B.; Alton, G.; Cui, J. J.; Kung, P. P.;
Nambu, M. D.; Los, G.; Bender, S. L.; Mroczkowski, B.; Christensen, J.
G. An orally available small-molecule inhibitor of c-Met, PF-2341066,
exhibits cytoreductive antitumor efficacy through antiproliferative and
antiangiogenic mechanisms. Cancer Res. 2007, 67, 4408−4417.
(12) Comoglio, P. M.; Giordano, S.; Trusolino, L. Drug development
of MET inhibitors: targeting oncogene addiction and expedience. Nat.
Rev. Drug Discovery 2008, 7, 504−516.
(13) Sakamoto, H.; Tsukaguchi, T.; Hiroshima, S.; Kodama, T.;
Kobayashi, T.; Fukami, T. A.; Oikawa, N.; Tsukuda, T.; Ishii, N.; Aoki,
Y. CH5424802, a selective ALK inhibitor capable of blocking the
resistant gatekeeper mutant. Cancer Cell 2011, 19, 679−690.
(14) Sasaki, T.; Janne, P. A. New strategies for treatment of ALK-
rearranged non-small cell lung cancers. Clin. Cancer Res. 2011, 17,
7213−7218.
(22) Zificsak, C. A.; Theroff, J. P.; Aimore, L. D.; Angeles, T. S.;
Albom, M. S.; Underiner, T. L.; Wan, W.; Dorsey, B. D.
Methanesulfonamido-cyclohexylamine derivatives of 2,4-diamino
pyrimidine as potent ALK inhibitors. Bioorg. Med. Chem. Lett. 2011,
21, 3877−3880.
(23) Zificsak, C. A.; Theroff, J. P.; Aimore, L. D.; Albom, M. S.;
Angeles, T. S.; Worrell, C. S.; Zeigler, K. S.; Dorsey, B. D. 2,4-
Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine
anilines. Bioorg. Med. Chem. Lett. 2011, 21, 660−663.
(24) Weinberg, L. R.; Albom, M. S.; Angeles, T. S.; Husten, J.; Lisko,
J. G.; McHugh, R. J.; Ott, G. R.; Tripathy, R.; Underiner, T. L.;
Zificsak, C. A.; Dorsey, B. D. Fused bicyclic derivatives of 2,4-
diaminopyrimidine as c-Met inhibitors. Bioorg. Med. Chem. Lett. 2011,
21, 164−167.
(25) Ott, G. R.; Tripathy, R.; Cheng, M.; McHugh, R.; Anzalone, A.
V.; Ator, M. A.; Ruggeri, B. A.; Dorsey, B. D. Discovery of a potent
inhibitor of anaplastic lymphoma kinase with in vivo antitumor
activity. ACS Med. Chem. Lett. 2010, 1, 493−499.
(26) Milkiewicz, K. L.; Aimone, L. D.; Albom, M. S.; Angeles, T. S.;
Chang, H.; Grobelny, J. V.; Husten, J.; LoSardo, C.; Underiner, T. L.;
Weinberg, L. R.; Worrell, C. S.; Zeigler, K. S.; Dorsey, B. D. Bioorg.
Med. Chem. 2011, 19, 6274−6284.
(27) Ye, N.; Chen, C.-H.; Chen, T. T.; Song, Z.; He, J.; Huan, X.;
Song, S.; Liu, Q.; Chen, Y.; Ding, J.; Xu, Y.; Miao, Z.; Zhang, A.
Design, synthesis and biological evaluation of a series of benzo[de]-
[1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain
appendage as novel PARP1 inhibitors. J. Med. Chem. 2013, 56, 2885−
2903.
(28) Zhang, J.; Xiong, B.; Zhen, X.; Zhang, A. Dopamine D1 receptor
ligands: Where are we now and where are we going. Med. Res. Rev.
2009, 29, 272−294.
(29) EI-Subbagh, H.; Wittig, T.; Decker, M.; Elz, S.; Nieger, M.;
Lehmann, J. Arch. Pharm. Pharm. Med. Chem. 2002, 9, 443−448.
(30) Ye, N.; Neumeyer, J. L.; Baldessarini, R. J.; Zhen, X.; Zhang, A.
Recent progress in the development of dopamine receptor subtype
compounds: Potential therapeutic agents for neurological and
neuropsychiatric disorders. Chem. Rev. 2013, 113, PR123−PR178.
(15) Wu, K.; Ai, J.; Liu, Q.; Chen, T.; Zhao, A.; Peng, X.; Wang, Y.;
Ji, Y.; Yao, Q.; Xu, Y.; Geng, M.; Zhang, A. Multisubstituted
quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study
as tyrosine kinase c-Met inhibitors. Bioorg. Med. Chem. Lett. 2012, 22,
6368−6372.
(16) Wang, Y. X.; Ai, J.; Yue, J. F.; Peng, X.; Ji, Y. C.; Zhao, A. L.;
Gao, X.; Wang, Y.; Chen, Y.; Liu, G.; Gao, Z. B.; Geng, M. Y.; Zhang,
A. Further SAR studies on 3,5-diamino-7-trifluoromethyl quinolines as
highly potent tyrosine kinase c-Met inhibitors: efforts to correct hERG
inhibition. MedChemComm 2012, 3, 1423−1427.
(17) Zhao, A.; Gao, X.; Wang, Y.; Ai, J.; Wang, Y.; Chen, Y.; Geng,
M.; Zhang, A. Discovery of novel c-Met kinase inhibitors bearing a
thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold. Bioorg.
Med. Chem. 2011, 19, 3906−3918.
(18) Wang, Y.; Ai, J.; Wang, Y.; Chen, Y.; Wang, L.; Liu, G.; Geng,
M.; Zhang, A. Synthesis and c-Met kinase inhibition of 3,5-
disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-
(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)-
quinoline as a novel anticancer agent. J. Med. Chem. 2011, 54,
2127−2142.
(19) Galkin, A. V.; Melnick, J. S.; Kim, S.; Hood, T. L.; Li, N.; Li, L.;
Xia, G.; Steensma, R.; Chopiuk, G.; Jiang, J.; Wan, Y.; Ding, P.; Liu, Y.;
Sun, F.; Schultz, P. G.; Gray, N. S.; Warmuth, M. Identification of
NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-
ALK. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 270−275.
(20) Gingrich, D. E.; Lisko, J. G.; Curry, M. A.; Cheng, M.;
Haltiwanger, R. C.; Wells-Knecht, K.; Ott, G. R.; Ghose, A. K.; Ator,
M. A.; Ruggeri, B.; Dorsey, B. D. Discovery of an orally efficacious
inhibitor of anaplastic lymphoma kinase. J. Med. Chem. 2012, 55,
4580−4593.
(21) Mesaros, E. F.; Burke, J. P.; Parrish, J. D.; Dugan, B. J.;
Anzalone, A. V.; Angeles, T. S.; Albom, M. S.; Ator, M. A.; Ruggeri, B.
A.; Cheng, M.; Ott, G. R.; Dorsey, B. D. Bioorg. Med. Chem. Lett. 2011,
463−466.
308
dx.doi.org/10.1021/ml400373j | ACS Med. Chem. Lett. 2014, 5, 304−308